Europe presents a unique epidemiological landscape for neurodegenerative diseases, characterized by:
| Region | Prevalence (65+) | Total Cases | Notes |
|---|---|---|---|
| Western Europe | 7-9% | ~5-6 million | Highest prevalence globally |
| Southern Europe | 6-8% | ~3-4 million | Italy, Spain, Portugal, Greece |
| Northern Europe | 5-7% | ~2-3 million | UK, Scandinavia, Netherlands |
| Central/Eastern Europe | 5-7% | ~3-4 million | Poland, Czech, Hungary, Romania |
| Total Europe | 6-8% | ~14-17 million |
| Country | Dementia Cases | % of Population | Notes |
|---|---|---|---|
| Germany | ~1.5 million | ~1.8% | Largest absolute burden |
| France | ~1.2 million | ~1.9% | Well-documented |
| Italy | ~1.1 million | ~1.8% | High longevity |
| United Kingdom | ~850,000 | ~1.3% | Underlying population size |
| Spain | ~800,000 | ~1.7% | Aging population |
| Poland | ~600,000 | ~1.5% | Growing rapidly |
| Netherlands | ~250,000 | ~1.5% | Excellent registry data |
| Sweden | ~200,000 | ~2.0% | Highest per capita |
| Belgium | ~200,000 | ~1.8% | |
| Austria | ~150,000 | ~1.7% |
| Region | 2025 | 2030 | 2040 | 2050 |
|---|---|---|---|---|
| Western Europe | 5.5M | 6.5M | 8M | 10M |
| Southern Europe | 3.5M | 4M | 5M | 6M |
| Northern Europe | 2.5M | 3M | 4M | 5M |
| Central/Eastern Europe | 3.5M | 4M | 5.5M | 7M |
| Total Europe | 15M | 17.5M | 22.5M | 28M |
| Country | Annual Cost (EUR billions) | Per-Patient Cost |
|---|---|---|
| Germany | ~€50 | ~€33,000 |
| France | ~€35 | ~€29,000 |
| UK | ~£30 (~$38B) | ~£35,000 |
| Italy | ~€25 | ~€23,000 |
| Spain | ~€18 | ~€22,000 |
| Total Europe | ~€200-250 billion | ~€25,000 |
| Region | Prevalence | Total Cases | Notes |
|---|---|---|---|
| Western Europe | 1-2% (65+) | ~1.5-2 million | Highest documentation |
| Southern Europe | 1-1.5% (65+) | ~0.8-1 million | |
| Northern Europe | 1-2% (65+) | ~0.6-0.8 million | |
| Central/Eastern Europe | 0.8-1.2% (65+) | ~0.8-1 million | |
| Total Europe | ~1.5% (65+) | ~4-5 million |
| Country | PD Cases | Notes |
|---|---|---|
| Germany | ~400,000 | Largest in Europe |
| France | ~300,000 | |
| Italy | ~250,000 | |
| UK | ~200,000 | |
| Spain | ~150,000 | |
| Poland | ~120,000 | Growing |
| Netherlands | ~60,000 | Excellent data |
| Sweden | ~50,000 | High quality |
| Belgium | ~40,000 | |
| Austria | ~35,000 |
| Year | Projected Prevalence |
|---|---|
| 2025 | 4-5 million |
| 2030 | 5-6 million |
| 2040 | 7-8 million |
| 2050 | 9-10 million |
| Metric | Value |
|---|---|
| Total prevalence | ~30,000-40,000 |
| Annual incidence | ~1-2 per 100,000 |
| Annual deaths | ~15,000-20,000 |
| Median survival | 2-4 years |
| Country | Estimated Cases |
|---|---|
| Germany | ~8,000 |
| France | ~6,000 |
| UK | ~5,000 |
| Italy | ~4,000 |
| Spain | ~3,000 |
| Poland | ~2,000 |
| Metric | Estimated Value |
|---|---|
| Total cases | ~80,000-120,000 |
| Mean age at onset | 50-60 years |
| Underdiagnosis factor | 2-3x |
Genetic Profile:
| Metric | Estimated Value |
|---|---|
| Gene carriers | ~100,000-150,000 |
| Manifest patients | ~35,000-50,000 |
| Highest prevalence | UK, Ireland, Scandinavia |
| Disorder | Estimated European Cases |
|---|---|
| MSA | ~30,000-50,000 |
| PSP | ~50,000-70,000 |
| CBS | ~15,000-25,000 |
| Disease | Prevalence (2025) | Projected 2050 | Economic Cost |
|---|---|---|---|
| Alzheimer's Disease | 14-17 million | 28 million | ~€250 billion |
| Parkinson's Disease | 4-5 million | 10 million | ~€40 billion |
| ALS | 30,000-40,000 | Stable | ~€3 billion |
| FTD | 80,000-120,000 | 150,000+ | ~€10 billion |
| Huntington's | 35,000-50,000 | Stable | ~€2 billion |